This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is Mallinckrodt (MNK) Down 24.8% Since Last Earnings Report?
by Zacks Equity Research
Mallinckrodt (MNK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mallinckrodt Gets FDA Committee Vote for Abuse-Deterrent Drug
by Zacks Equity Research
The FDA's Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee vote for Mallinckrodt (MNK) abuse-deterrent drug.
Mallinckrodt (MNK) Beats on Q3 Earnings Estimates, Ups View
by Zacks Equity Research
Mallinckrodt (MNK) surpasses both earnings and sales estimates in the third quarter of 2018.
Company News For Nov 7, 2018
by Zacks Equity Research
Companies In The News Are: ELF,ABC,MNK,MYL
September JOLTS Report In Spotlight
by Zacks Equity Research
September JOLTS Report In Spotlight
Playing the Waiting Game; Plus MedTech, Pharma in Q3 Earnings
by Mark Vickery
We won't get the final numbers until later, so until then we're just playing the waiting game.
MNK or AMPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MNK vs. AMPH: Which Stock Is the Better Value Option?
Should Value Investors Buy Mallinckrodt (MNK) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Mallinckrodt (MNK) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Mallinckrodt (MNK) delivered earnings and revenue surprises of 16.67% and 0.53%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Mallinckrodt (MNK) Q3 Earnings Expected to Decline
by Zacks Equity Research
Mallinckrodt (MNK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mallinckrodt (MNK) Gets $26 Million as Funding From BARDA
by Zacks Equity Research
Mallinckrodt (MNK) gets $26 million for additional funding from BARDA for pediatric studies of StrataGraft skin tissue in thermal burns.
Generic-Drugs Stock Outlook: No Respite from Pricing Issues
by Zacks Equity Research
Generic drugmakers, in general, are having a rather poor year, primarily due to ongoing pricing pressure and rising competition.
MNK or AMPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MNK vs. AMPH: Which Stock Is the Better Value Option?
Forget Mylan, Invest in These 3 Generic/Drug Stocks Instead
by Ekta Bagri
Given the recent spate of setbacks suffered by Mylan (MYL), we suggest investing in better-ranked generic/drug companies with favorable growth profile.
Is Mallinckrodt (MNK) a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if Mallinckrodt (MNK) stock is a good choice for value-oriented investors right now from multiple angles.
Why Is Mallinckrodt (MNK) Up 14.9% Since Last Earnings Report?
by Zacks Equity Research
Mallinckrodt (MNK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Top Ranked Value Stocks to Buy for August 31st
by Zacks Equity Research
Here are three stocks with buy rank and strong value characteristics for investors to consider today, August 31st:
Are Investors Undervaluing Mallinckrodt (MNK) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Mallinckrodt's Stannsoporfin Gets Complete Response Letter
by Zacks Equity Research
Mallinckrodt's (MNK) pipeline candidate, Stannsoporfin gets a Complete Response Letter from the FDA.
Evoke Pharma (EVOK) Announces FDA Acceptance of Gimoti NDA
by Zacks Equity Research
The FDA accepts Evoke Pharma's (EVOK) regulatory application seeking approval of its pipeline candidate, Gimoti, for treating diabetic gastroparesis. Shares up.
Moving Average Crossover Alert: Mallinckrodt Public (MNK)
by Zacks Equity Research
Mallinckrodt Public Limited Company (MNK) is looking like an interesting pick from a technical perspective
MNK vs. AMPH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MNK vs. AMPH: Which Stock Is the Better Value Option?
Mallinckrodt (MNK) Beats on Q2 Earnings and Sales, Ups View
by Zacks Equity Research
Mallinckrodt (MNK) surges following earnings and sales beat in the second quarter. Increase in annual guidance is impressive as well.
Company News For Aug 8, 2018
by Zacks Equity Research
Companies In The News are: ETSY,Z,DISCA,MNK
Options Traders Expect Huge Moves in Mallinckrodt (MNK) Stock
by Zacks Equity Research
Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.